Loading…
For the People Act of 2021
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
79pct
66d open
vs 9,698 other HR bills in the 117th — cohort avg 63d
For the People Act of 2021 This bill addresses voter access, election integrity and security, campaign finance, and ethics for the three branches of government. Specifically, the bill expands voter registration (e.g., automatic and same-day registration) and voting access (e.g., vote-by-mail and early voting). It also limits removing voters from voter rolls. The bill requires states to establish independent redistricting commissions to carry out congressional redistricting. Additionally, the bill sets forth provisions related to election security, including sharing intelligence information with state election officials, supporting states in securing their election systems, developing a national strategy to protect U.S. democratic institutions, establishing in the legislative branch the National Commission to Protect United States Democratic Institutions, and other provisions to improve the cybersecurity of election systems. Further, the bill addresses campaign finance, including by expanding the prohibition on campaign spending by foreign nationals, requiring additional disclosure of campaign-related fundraising and spending, requiring additional disclaimers regarding certain political advertising, and establishing an alternative campaign funding system for certain federal offices. The bill addresses ethics in all three branches of government, including by requiring a code of conduct for Supreme Court Justices, prohibiting Members of the House from serving on the board of a for-profit entity, and establishing additional conflict-of-interest and ethics provisions for federal employees and the White House. The bill requires the President, the Vice President, and certain candidates for those offices to disclose 10 years of tax returns.
Yes
1521
No
1902
Present
0
Not Voting
26
Party Breakdown
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Received in the Senate.
The Clerk was authorized to correct section numbers, punctuation, and cross references, and to make other necessary technical and conforming corrections in the engrossment of H.R. 1.
Motion to reconsider laid on the table Agreed to without objection.
On passage Passed by the Yeas and Nays: 220 - 210 (Roll no. 62).
HousePassed/agreed to in House: On passage Passed by the Yeas and Nays: 220 - 210 (Roll no. 62).
HouseOn motion to recommit Failed by the Yeas and Nays: 210 - 219 (Roll no. 61).
HouseConsidered as unfinished business. (consideration: CR H1071-1072)
Pursuant to clause 1(c) of Rule XIX, the House resumed with further consideration of H.R. 1.
Pursuant to clause 1(c) of Rule XIX, further consideration of H.R. 1 was postponed.
Bills with similar content found using semantic analysis.
Sources: Congress.gov · House Clerk roll-call votes
| house |
| On Agreeing to the Amendment |
Failed |
| March 3, 2021 |
| #62 | house | On Passage | Passed | March 3, 2021 |
| #58 | house | On Agreeing to the Amendment | Agreed to | March 3, 2021 |
| #61 | house | On Motion to Recommit | Failed | March 3, 2021 |
| #54 | house | On Agreeing to the Amendment | Failed | March 2, 2021 |
| #53 | house | On Agreeing to the Amendment | Failed | March 2, 2021 |
| #55 | house | On Agreeing to the Amendment | Agreed to | March 2, 2021 |
| #52 | house | On Agreeing to the Amendment | Agreed to | March 2, 2021 |
2026 · third_quarter · Taxation/Internal Revenue Code
The One Big Beautiful Bill Act (H.R.1): issues related to the tax treatment of retirement savings. Implementation of SECURE 2.0 Act of 2022. Retirement Savings for Americans Act. Allowing 403(b) plans to invest in collective investment trusts. Capital gains and dividends taxation. Excise tax on corporate stock buybacks.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Environment/Superfund
Issues related to the implementation of H.R. 3684, the Infrastructure Investment and Jobs Act (IIJA). Issues related to Buy America. Issues related to energy and environmental permitting reform. Issues related to permitting reform in H.R. 1, the Lower Energy Costs Act. Issues related to the implementation of H.R. 5376, the Inflation Reduction Act of 2022.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Transportation, Dept of (DOT)
2026 · third_quarter · Taxation/Internal Revenue Code
HR 1 / PL 119-21 One Big Beautiful Bill Act. HR 2547/S 1335 Secure Family Futures Act. Issue: debt investment tax change from capital to ordinary. Public Law 117-169. Issue: implementation of corporate minimum tax. S ___ Protecting Proper Life Insurance (PPLI) from Abuse Act. Issue: private placement life insurance. No bill number. Issue: life insurance tax stabilization.
Client expense: $240,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Medicare/Medicaid
H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 4299: Protecting Patient Access to Cancer and Complex Therapies Act H.R. 10628: Biosimilars Access and Affordability Act S. 5571: Biosimilars Access and Affordability Act Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues Part D redesign and policy issues including non-interference and rebates policy issues Part B policy issues Drug cost and pricing policy issues Medicare rebate policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues CMS IPAY Guidance on the Medicare Drug Price Negotiation Program IPAY and Maximum Fair Prices policy issues Medicaid rebate policy issues GENErating cost Reductions for U.S. Medicaid (GENEROUS) model Global Benchmark for Efficient Drug Pricing (GLOBE) Proposed Rule Guarding U.S. Medicare Against Rising Drugs Costs (GUARD) Proposed Rule
Client expense: $1,530,000 · Firm income: Not reported
2026 · third_quarter · Health Issues
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act H.R.5526 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act HR 7391 Community Health Center Drug Pricing Protection Act HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act (Reconciliation 2.0) S 3014 Ensuring Timely Access to Generics Act of 2025 S 2355 Patients Deserve Price Tags Act HR 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 HR 8800 National Defense Authorization Act for Fiscal year 2027 HR 9102 BINSA Bill COINS Act, enacted within P.L. 119-60 National Defense Authorization Act for Fiscal Year 2026 S 1414 Expedited Access to Biosimilars Act HR 10628/ S 5571 Biosimilars Access and Affordability Act S 5244 Sustain 340B Act HR 9599 Secure 340B Act HR 5509/ S 2903 Safe Step Act
POSTPONED PROCEEDINGS - The Chair put the question on the motion to recommit and by voice vote, announced that the noes had prevailed. Mr. Rodney Davis (IL) demanded the yeas and nays and the Chair postponed further proceedings until a time to be announced.
The previous question on the motion to recommit was ordered pursuant to the rule.
Mr. Davis, Rodney moved to recommit to the Committee on House Administration. (text: CR H1039)
Considered as unfinished business. (consideration: CR H1039)
POSTPONED PROCEEDINGS - Pursuant to clause 1(c) of Rule 19, further consideration of H.R. 1 was postponed.
The previous question was ordered pursuant to the rule.
Considered as unfinished business. (consideration: CR H1037-1038)
POSTPONED PROCEEDINGS - At the conclusion of debate on the Lofgren amendment en bloc No. 4, the Chair put the question on agreeing to the amendment and by voice vote, announced that the ayes had prevailed. Mr. Gohmert demanded the yeas and nays and the Chair postponed further proceedings until a time to be announced.
DEBATE - Pursuant to the provisions of H. Res. 179, the House proceeded with 20 minutes of debate on the Lofgren amendment en bloc No. 4.
POSTPONED PROCEEDINGS - At the conclusion of debate on the Pressley amendment, the Chair put the question on the agreeing to the amendment and by voice vote, announced that the noes had prevailed. Mr. Rodney Davis (IL) demanded yeas and nays and the Chair postponed further proceedings until a time to be announced.
DEBATE - Pursuant to the provisions of H. Res. 179, the House proceeded with 10 minutes of debate on the Pressley amendment No. 37.
Motion to reconsider laid on the table. Agreed to without objection.
DEBATE - Pursuant to the provisions of H. Res. 179, the House proceeded with 10 minutes of debate on the Lesko amendment No. 28.
Considered as unfinished business. (consideration: CR H1023-1037)
Pursuant to clause 1(c) of Rule XIX, the House resumed consideration of H.R. 1.
Pursuant to clause 1(c) of Rule XIX, further consideration of H.R. 1 is postponed.
Motion to reconsider laid on the table. Agreed to without objection.
UNFINISHED BUSINESS - The Chair announced that the unfinished business was the question on agreeing to the amendments which had been debated earlier and on which further proceedings had been postponed.
Considered as unfinished business. (consideration: CR H1009-1010)
POSTPONED PROCEEDINGS - At the conclusion of debate on the Lofgren amendment en bloc No. 3, the Chair put the question on agreeing to the amendment and by voice vote, announced that the noes had prevailed. Ms. Lofgren demanded the yeas and nays and the Chair postponed further proceedings until a time to be announced.
DEBATE - Pursuant to the provisions of H.Res. 179, the House proceeded with 20 minutes of debate on the Lofgren amendment en bloc No. 3.
POSTPONED PROCEEDINGS - At the conclusion of debate on the Rodney Davis (IL) amendment No. 19, the Chair put the question on the agreeing to the amendment and by voice vote, announced that the nays had prevailed. Ms. Lofgren demanded yeas and nays and the Chair postponed further proceedings until a time to be announced.
DEBATE - Pursuant to the provisions of H.Res. 179, the House proceeded with 10 minutes of debate on the Rodney Davis (IL) amendment No. 19.
POSTPONED PROCEEDINGS - At the conclusion of debate on the Bush amendment No. 14, the Chair put the question on the agreeing to the amendment and by voice vote, announced that the ayes had prevailed. Mrs. Green(GA) demanded yeas and nays and the Chair postponed further proceedings until a time to be announced.
DEBATE - Pursuant to the provisions of H.Res. 179, the House proceeded with 10 minutes of debate on the Bush amendment No. 14.
DEBATE - Pursuant to the provisions of H.Res. 179, the House proceeded with 20 minutes of debate on the Lofgren amendment en bloc No. 2.
POSTPONED PROCEEDINGS - At the conclusion of debate on the Lofgren amendment en bloc No. 1, the Chair put the question on agreeing to the amendment and by voice vote, announced that the noes had prevailed. Ms. Lofgren demanded the yeas and nays and the Chair postponed further proceedings until a time to be announced.
DEBATE - Pursuant to the provisions of H.Res. 179, the House proceeded with 20 minutes of debate on the Lofgren amendment en bloc No. 1.
DEBATE - The House proceeded with one hour of debate on H.R. 1.
Rule provides for consideration of H.R. 1 and H.R. 1280. Rule provides for 1 hour of general debate on H.R. 1 and one motion to recommit. Rule provides for 1 hour of general debate on H.R. 1280 and one motion to recommit.
Considered under the provisions of rule H. Res. 179. (consideration: CR H886-1009; text: CR H886-972)
Rules Committee Resolution H. Res. 179 Reported to House. Rule provides for consideration of H.R. 1 and H.R. 1280. Rule provides for 1 hour of general debate on H.R. 1 and one motion to recommit. Rule provides for 1 hour of general debate on H.R. 1280 and one motion to recommit.
Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.
Referred to the Subcommittee on the Constitution, Civil Rights, and Civil Liberties.
Referred to the Subcommittee on Cybersecurity, Infrastructure Protection, and Innovation.
Referred to the Subcommittee on Research and Technology.
Referred to the Committee on House Administration, and in addition to the Committees on Intelligence (Permanent Select), the Judiciary, Oversight and Reform, Science, Space, and Technology, Education and Labor, Ways and Means, Financial Services, Ethics, Homeland Security, and Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Congress.gov source codes: 1000, Intro-H
| Referred to |
| January 4, 2021 |
| Ethics Committee | House | Referred to | January 4, 2021 |
| Financial Services Committee | House | Referred to | January 4, 2021 |
| Ways and Means Committee | House | Referred to | January 4, 2021 |
| Education and the Workforce Committee | House | Referred to | January 4, 2021 |
| Oversight and Accountability Committee | House | Referred to | January 4, 2021 |
| Intelligence (Permanent Select) Committee | House | Referred to | January 4, 2021 |
| Committee on House Administration | House | Referred to | January 4, 2021 |
| Democratic |
| WA |
| Adriano Espaillat | Democratic | NY |
| Al Green | Democratic | TX |
| Al Lawson, Jr. | Democratic | FL |
| Alan S. Lowenthal | Democratic | CA |
| Albio Sires | Democratic | NJ |
| Alcee L. Hastings | Democratic | FL |
| Alexandria Ocasio-Cortez | Democratic | NY |
| Alma S. Adams | Democratic | NC |
| Ami Bera | Democratic | CA |
| André Carson | Democratic | IN |
| Andy Kim | Democratic | NJ |
| Andy Levin | Democratic | MI |
| Angie Craig | Democratic | MN |
| Ann Kirkpatrick | Democratic | AZ |
| Ann M. Kuster | Democratic | NH |
| Anna G. Eshoo | Democratic | CA |
| Anthony G. Brown | Democratic | MD |
| Antonio Delgado | Democratic | NY |
| Ayanna Pressley | Democratic | MA |
| Barbara Lee | Democratic | CA |
| Bennie G. Thompson | Democratic | MS |
| Betty McCollum | Democratic | MN |
| Bill Foster | Democratic | IL |
| Bill Pascrell, Jr. | Democratic | NJ |
| Bobby L. Rush | Democratic | IL |
| Bonnie Watson Coleman | Democratic | NJ |
| Brad Sherman | Democratic | CA |
| Bradley Scott Schneider | Democratic | IL |
| Brenda L. Lawrence | Democratic | MI |
| Brendan F. Boyle | Democratic | PA |
| Brian Higgins | Democratic | NY |
| C. A. Dutch Ruppersberger | Democratic | MD |
| Carolyn B. Maloney | Democratic | NY |
| Carolyn Bourdeaux | Democratic | GA |
| Charlie Crist | Democratic | FL |
| Chellie Pingree | Democratic | ME |
| Cheri Bustos | Democratic | IL |
| Chris Pappas | Democratic | NH |
| Chrissy Houlahan | Democratic | PA |
| Colin Z. Allred | Democratic | TX |
| Conor Lamb | Democratic | PA |
| Cori Bush | Democratic | MO |
| Cynthia Axne | Democratic | IA |
| Daniel T. Kildee | Democratic | MI |
| Danny K. Davis | Democratic | IL |
| Darren Soto | Democratic | FL |
| David E. Price | Democratic | NC |
| David J. Trone | Democratic | MD |
| David N. Cicilline | Democratic | RI |
| David Scott | Democratic | GA |
| Dean Phillips | Democratic | MN |
| Debbie Dingell | Democratic | MI |
| Debbie Wasserman Schultz | Democratic | FL |
| Deborah K. Ross | Democratic | NC |
| Debra A. Haaland | Democratic | NM |
| Derek Kilmer | Democratic | WA |
| Diana DeGette | Democratic | CO |
| Dina Titus | Democratic | NV |
| Donald M. Payne, Jr. | Democratic | NJ |
| Donald Norcross | Democratic | NJ |
| Donald S. Beyer, Jr. | Democratic | VA |
| Doris O. Matsui | Democratic | CA |
| Dwight Evans | Democratic | PA |
| Earl Blumenauer | Democratic | OR |
| Ed Case | Democratic | HI |
| Ed Perlmutter | Democratic | CO |
| Eddie Bernice Johnson | Democratic | TX |
| Elaine G. Luria | Democratic | VA |
| Eleanor Holmes Norton | Democratic | DC |
| Elissa Slotkin | Democratic | MI |
| Emanuel Cleaver | Democratic | MO |
| Eric Swalwell | Democratic | CA |
| Filemon Vela | Democratic | TX |
| Frank J. Mrvan | Democratic | IN |
| Frank Pallone, Jr. | Democratic | NJ |
| Frederica S. Wilson | Democratic | FL |
| G. K. Butterfield | Democratic | NC |
| Gerald E. Connolly | Democratic | VA |
| Grace F. Napolitano | Democratic | CA |
| Grace Meng | Democratic | NY |
| Greg Stanton | Democratic | AZ |
| Gregory W. Meeks | Democratic | NY |
| Gwen Moore | Democratic | WI |
| Hakeem S. Jeffries | Democratic | NY |
| Haley M. Stevens | Democratic | MI |
| Henry C. "Hank" Johnson, Jr. | Democratic | GA |
| Henry Cuellar | Democratic | TX |
| Ilhan Omar | Democratic | MN |
| J. Luis Correa | Democratic | CA |
| Jackie Speier | Democratic | CA |
| Jahana Hayes | Democratic | CT |
| Jake Auchincloss | Democratic | MA |
| Jamaal Bowman | Democratic | NY |
| James A. Himes | Democratic | CT |
| James E. Clyburn | Democratic | SC |
| James P. McGovern | Democratic | MA |
| James R. Langevin | Democratic | RI |
| Jamie Raskin | Democratic | MD |
| Janice D. Schakowsky | Democratic | IL |
| Jared F. Golden | Democratic | ME |
| Jared Huffman | Democratic | CA |
| Jason Crow | Democratic | CO |
| Jennifer Wexton | Democratic | VA |
| Jerrold Nadler | Democratic | NY |
| Jerry McNerney | Democratic | CA |
| Jesús G. "Chuy" García | Democratic | IL |
| Jim Cooper | Democratic | TN |
| Jim Costa | Democratic | CA |
| Jimmy Gomez | Democratic | CA |
| Jimmy Panetta | Democratic | CA |
| Joaquin Castro | Democratic | TX |
| Joe Courtney | Democratic | CT |
| Joe Neguse | Democratic | CO |
| John A. Yarmuth | Democratic | KY |
| John B. Larson | Democratic | CT |
| John Garamendi | Democratic | CA |
| Joseph D. Morelle | Democratic | NY |
| Josh Gottheimer | Democratic | NJ |
| Josh Harder | Democratic | CA |
| Joyce Beatty | Democratic | OH |
| Juan Vargas | Democratic | CA |
| Judy Chu | Democratic | CA |
| Julia Brownley | Democratic | CA |
| Kaiali’i Kahele | Democratic | HI |
| Karen Bass | Democratic | CA |
| Katherine M. Clark | Democratic | MA |
| Kathleen M. Rice | Democratic | NY |
| Kathy Castor | Democratic | FL |
| Kathy E. Manning | Democratic | NC |
| Katie Porter | Democratic | CA |
| Kim Schrier | Democratic | WA |
| Kurt Schrader | Democratic | OR |
| Kweisi Mfume | Democratic | MD |
| Lauren Underwood | Democratic | IL |
| Linda T. Sánchez | Democratic | CA |
| Lisa Blunt Rochester | Democratic | DE |
| Lizzie Fletcher | Democratic | TX |
| Lloyd Doggett | Democratic | TX |
| Lois Frankel | Democratic | FL |
| Lori Trahan | Democratic | MA |
| Lucille Roybal-Allard | Democratic | CA |
| Lucy McBath | Democratic | GA |
| Madeleine Dean | Democratic | PA |
| Marc A. Veasey | Democratic | TX |
| Marcia L. Fudge | Democratic | OH |
| Marcy Kaptur | Democratic | OH |
| Marie Newman | Democratic | IL |
| Marilyn Strickland | Democratic | WA |
| Mark DeSaulnier | Democratic | CA |
| Mark Pocan | Democratic | WI |
| Mark Takano | Democratic | CA |
| Mary Gay Scanlon | Democratic | PA |
| Matt Cartwright | Democratic | PA |
| Maxine Waters | Democratic | CA |
| Michael F. Doyle | Democratic | PA |
| Mike Levin | Democratic | CA |
| Mike Quigley | Democratic | IL |
| Mike Thompson | Democratic | CA |
| Mikie Sherrill | Democratic | NJ |
| Mondaire Jones | Democratic | NY |
| Nancy Pelosi | Democratic | CA |
| Nanette Diaz Barragán | Democratic | CA |
| Nikema Williams | Democratic | GA |
| Norma J. Torres | Democratic | CA |
| Nydia M. Velázquez | Democratic | NY |
| Paul Tonko | Democratic | NY |
| Pete Aguilar | Democratic | CA |
| Peter A. DeFazio | Democratic | OR |
| Peter Welch | Democratic | VT |
| Pramila Jayapal | Democratic | WA |
| Raja Krishnamoorthi | Democratic | IL |
| Rashida Tlaib | Democratic | MI |
| Raul Ruiz | Democratic | CA |
| Raúl M. Grijalva | Democratic | AZ |
| Richard E. Neal | Democratic | MA |
| Rick Larsen | Democratic | WA |
| Ritchie Torres | Democratic | NY |
| Ro Khanna | Democratic | CA |
| Robert C. "Bobby" Scott | Democratic | VA |
| Robin L. Kelly | Democratic | IL |
| Ron Kind | Democratic | WI |
| Rosa L. DeLauro | Democratic | CT |
| Ruben Gallego | Democratic | AZ |
| Salud O. Carbajal | Democratic | CA |
| Sanford D. Bishop, Jr. | Democratic | GA |
| Sara Jacobs | Democratic | CA |
| Scott H. Peters | Democratic | CA |
| Sean Casten | Democratic | IL |
| Sean Patrick Maloney | Democratic | NY |
| Seth Moulton | Democratic | MA |
| Sharice Davids | Democratic | KS |
| Sheila Jackson Lee | Democratic | TX |
| Stacey E. Plaskett | Democratic | VI |
| Steny H. Hoyer | Democratic | MD |
| Stephanie N. Murphy | Democratic | FL |
| Stephen F. Lynch | Democratic | MA |
| Steve Cohen | Democratic | TN |
| Steven Horsford | Democratic | NV |
| Susan Wild | Democratic | PA |
| Susie Lee | Democratic | NV |
| Suzan K. DelBene | Democratic | WA |
| Suzanne Bonamici | Democratic | OR |
| Sylvia R. Garcia | Democratic | TX |
| Ted Lieu | Democratic | CA |
| Teresa Leger Fernandez | Democratic | NM |
| Terri A. Sewell | Democratic | AL |
| Theodore E. Deutch | Democratic | FL |
| Thomas R. Suozzi | Democratic | NY |
| Tim Ryan | Democratic | OH |
| Tom Malinowski | Democratic | NJ |
| Tom O’Halleran | Democratic | AZ |
| Tony Cárdenas | Democratic | CA |
| Val Butler Demings | Democratic | FL |
| Veronica Escobar | Democratic | TX |
| Vicente Gonzalez | Democratic | TX |
| William R. Keating | Democratic | MA |
| Yvette D. Clarke | Democratic | NY |
| Zoe Lofgren | Democratic | CA |
| S 481 |
117th |
| Related bill |
| S 443 | 117th | Related bill |
| S 428 | 117th | Related bill |
| S 416 | 117th | Related bill |
| S 3345 | 117th | Related bill |
| S 3136 | 117th | Related bill |
| S 2671 | 117th | Related bill |
| S 2670 | 117th | Related bill |
| S 2512 | 117th | Related bill |
| S 2093 | 117th | Related bill |
| S 1 | 117th | Related bill |
| HRES 181 | 117th | Related bill |
| HRES 179 | 117th | Procedurally-related |
| HR 990 | 117th | Related bill |
| HR 989 | 117th | Related bill |
| HR 966 | 117th | Related bill |
| HR 827 | 117th | Related bill |
| HR 776 | 117th | Related bill |
| HR 775 | 117th | Related bill |
| HR 7134 | 117th | Related bill |
| HR 65 | 117th | Related bill |
| HR 642 | 117th | Related bill |
| HR 641 | 117th | Related bill |
| HR 640 | 117th | Related bill |
| HR 639 | 117th | Related bill |
| HR 6177 | 117th | Related bill |
| HR 5841 | 117th | Related bill |
| HR 576 | 117th | Related bill |
| HR 4766 | 117th | Related bill |
| HR 422 | 117th | Related bill |
| HR 403 | 117th | Related bill |
| HR 3867 | 117th | Related bill |
| HR 347 | 117th | Related bill |
| HR 337 | 117th | Related bill |
| HR 327 | 117th | Related bill |
| HR 2605 | 117th | Related bill |
| HR 244 | 117th | Related bill |
| HR 2358 | 117th | Related bill |
| HR 231 | 117th | Related bill |
| HR 1572 | 117th | Related bill |
| HR 1530 | 117th | Related bill |
| HR 1516 | 117th | Related bill |
| HR 1515 | 117th | Related bill |
| HR 1461 | 117th | Related bill |
| HR 1422 | 117th | Related bill |
| HR 1419 | 117th | Related bill |
| HR 1414 | 117th | Related bill |
| HR 134 | 117th | Related bill |
| HR 1334 | 117th | Related bill |
| HR 1312 | 117th | Related bill |
| HR 1279 | 117th | Related bill |
| HR 1278 | 117th | Related bill |
| HR 1274 | 117th | Related bill |
| HR 126 | 117th | Related bill |
| HR 1245 | 117th | Related bill |
| HR 1237 | 117th | Related bill |
| HR 1172 | 117th | Related bill |
| HR 1171 | 117th | Related bill |
| HR 1077 | 117th | Related bill |
| HR 1059 | 117th | Related bill |
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
Client expense: $3,150,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · third_quarter · Taxation/Internal Revenue Code
Monitor and engage on federal legislation and administrative action related to modifications to international corporate taxes, including the Net CFC Tested Income (NCTI, formerly GILTI) tax, Base Erosion and Anti-Abuse Tax (BEAT), and Foreign-Derived Deduction Eligible Income (FDDEI, formerly FDII) tax. Monitor and engage on federal legislation and administrative action related to modifications to international corporate taxes proposed by the Organisation for Economic Co-operation and Development (OECD) BEPS 2.0 process Pillar 2 global minimum tax rules. Monitor and engage on federal legislation and administrative action related to modifications to the corporate tax rate. Monitor and engage on federal legislation and administrative action related to extension of full expensing for research and development. Monitor and engage on federal legislation and administrative action related to Superfund tax, including but not limited to S. 615, Chemical Tax Repeal Act, and H.R. 640, Chemical Tax Repeal Act. Monitor and engage on federal legislation and administrative action related to taxation and deductibility of corporate interest payments. Monitor and engage on federal legislation and administrative action related to implementation of P.L. 117-169, Inflation Reduction Act of 2022. Monitor and engage on tax credits for recycling infrastructure. Monitor and engage on federal legislation and administrative action related to bonus depreciation tax incentives. Monitor and engage on the implementation of H.R.1, One Big Beautiful Bill Act (P.L. 119-21). H.R. 4466, CIRCLE Act. S. 1605, International Competition for American Jobs Act.
Client expense: $1,450,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
2026 · third_quarter · Taxation/Internal Revenue Code
H.R. 1, One Big Beautiful Bill Act" (PL 119-21) implementation, regulations. " Inflation Reduction Act of 2022" (PL 117-169), regulations and implementation."
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Taxation/Internal Revenue Code
Issues related to tax incentives for retirement savings. Issues related to electronic delivery of IRC- and ERISA-mandated statements and disclosures. Issues related to recordkeeping simplification for 401(k) plans. Issues related to lifetime income and auto features. Issues related to alternative investments in retirement plans. SECURE 2.0 Act of 2022 and Technical Corrections. S. 1831, Auto Reenroll Act. H.R. 1. H.R. 2958, Balance the Scales Act. H.R. 2869, EBSA Investigations Transparency Act. H.R. 6084, ERISA Litigation Reform Act. S. 4498, ABLE Tomorrow Act.
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Energy/Nuclear
-Issues related to energy efficiency tax credits in the Inflation Reduction Act of 2022 (H.R.5376) -Issues related to the One Big Beautiful Bill Act (H.R.1) -Issues related to the ENERGY STAR program
Client expense: $50,000 · Firm income: Not reported
Government targets: Energy, Dept of, Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Environment/Superfund
Issues related to the implementation of H.R. 3684, the Infrastructure Investment and Jobs Act (IIJA). Issues related to Buy America. Issues related to energy and environmental permitting reform. Issues related to permitting reform in H.R. 1, the Lower Energy Costs Act. Issues related to the implementation of H.R. 5376, the Inflation Reduction Act of 2022.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Transportation, Dept of (DOT)
2026 · second_quarter · Taxation/Internal Revenue Code
The One Big Beautiful Bill Act (H.R.1): issues related to the tax treatment of retirement savings. Implementation of SECURE 2.0 Act of 2022. Retirement Savings for Americans Act. Allowing 403(b) plans to invest in collective investment trusts. Capital gains and dividends taxation. Excise tax on corporate stock buybacks.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Taxation/Internal Revenue Code
HR 1 / PL 119-21 One Big Beautiful Bill Act. HR 2547/S 1335 Secure Family Futures Act. Issue: debt investment tax change from capital to ordinary. Public Law 117-169. Issue: implementation of corporate minimum tax. S ___ Protecting Proper Life Insurance (PPLI) from Abuse Act. Issue: private placement life insurance. No bill number. Issue: life insurance tax stabilization.
Client expense: $270,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Taxation/Internal Revenue Code
Implementation of H.R.5376, Inflation Reduction Act of 2022 Implementation of H.R. 1- The One Big Beautiful Bill Act
Client expense: $230,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Health Issues
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act H.R.5526 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act HR 7391 Community Health Center Drug Pricing Protection Act HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act (Reconciliation 2.0) S 3014 Ensuring Timely Access to Generics Act of 2025 S 2355 Patients Deserve Price Tags Act HR 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 HR 8800 National Defense Authorization Act for Fiscal year 2027 HR 9102 BINSA Bill COINS Act, enacted within P.L. 119-60 National Defense Authorization Act for Fiscal Year 2026 S 1414 Expedited Access to Biosimilars Act
Client expense: $2,440,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · second_quarter · Medicare/Medicaid
Treat and Reduce Obesity Act; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169) implementation. Pharmacy benefit manager reform proposals. H.R. 1, One Big Beautiful Bill Act, issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Medicare/Medicaid
General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. IPI drug pricing proposal, Medicare Rebate Rule. Drug pricing legislation, Medicare rebate reform, and proposals to impose "most favored nation" pricing on Medicare Part B and D. "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 1492 and S. 832. H.R. 1, "One Big Beautiful Bill Act", issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Taxation/Internal Revenue Code
Monitor and engage on federal legislation and administrative action related to modifications to international corporate taxes, including scheduled effective rate increases in the Global Intangible Low-Taxed Income (GILTI) tax, Base Erosion and Anti-Abuse Tax (BEAT), and Foreign-Derived Intangible Income (FDII) tax. Monitor and engage on federal legislation and administrative action related to modifications to international corporate taxes proposed by the Organisation for Economic Co-operation and Development (OECD) BEPS 2.0 process Pillar 2 global minimum tax rules. Monitor and engage on federal legislation and administrative action related to modifications to the corporate tax rate. Monitor and engage on federal legislation and administrative action related to extension of full expensing for research and development. Monitor and engage on federal legislation and administrative action related to Superfund tax, including but not limited to S. 615, Chemical Tax Repeal Act, and H.R. 640, Chemical Tax Repeal Act. Monitor and engage on federal legislation and administrative action related to taxation and deductibility of corporate interest payments. Monitor and engage on federal legislation and administrative action related to implementation of P.L. 117-169, Inflation Reduction Act of 2022. Monitor and engage on tax credits for recycling infrastructure. Monitor and engage on federal legislation and administrative action related to bonus depreciation tax incentives. Monitor and engage on the implementation of H.R.1, One Big Beautiful Bill Act (P.L. 119-21). H.R. 4466, CIRCLE Act. S. 1605, International Competition for American Jobs Act.
Client expense: $1,690,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
2026 · second_quarter · Taxation/Internal Revenue Code
Monitor and engage on federal legislation and administrative action related to modifications to international corporate taxes, including scheduled effective rate increases in the Global Intangible Low-Taxed Income (GILTI) tax, Base Erosion and Anti-Abuse Tax (BEAT), and Foreign-Derived Intangible Income (FDII) tax. Monitor and engage on federal legislation and administrative action related to modifications to international corporate taxes proposed by the Organisation for Economic Co-operation and Development (OECD) BEPS 2.0 process Pillar 2 global minimum tax rules. Monitor and engage on federal legislation and administrative action related to modifications to the corporate tax rate. Monitor and engage on federal legislation and administrative action related to extension of full expensing for research and development. Monitor and engage on federal legislation and administrative action related to Superfund tax, including but not limited to S. 615, Chemical Tax Repeal Act, and H.R. 640, Chemical Tax Repeal Act. Monitor and engage on federal legislation and administrative action related to taxation and deductibility of corporate interest payments. Monitor and engage on federal legislation and administrative action related to implementation of P.L. 117-169, Inflation Reduction Act of 2022. Monitor and engage on tax credits for recycling infrastructure. Monitor and engage on federal legislation and administrative action related to bonus depreciation tax incentives. Monitor and engage on the implementation of H.R.1, One Big Beautiful Bill Act (P.L. 119-21). H.R. 4466, CIRCLE Act. S. 1605, International Competition for American Jobs Act.
Client expense: $1,050,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
2026 · second_quarter · Taxation/Internal Revenue Code
H.R. 1, One Big Beautiful Bill Act" (PL 119-21) implementation, regulations. " Inflation Reduction Act of 2022" (PL 117-169), regulations and implementation."
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Taxation/Internal Revenue Code
Issues related to tax incentives for retirement savings. Issues related to electronic delivery of IRC- and ERISA-mandated statements and disclosures. Issues related to recordkeeping simplification for 401(k) plans. Issues related to lifetime income and auto features. Issues related to alternative investments in retirement plans. Technical Corrections to the SECURE 2.0 Act of 2022. S. 1831, Auto Reenroll Act. H.R. 1. H.R. 2958, Balance the Scales Act. H.R. 2869, EBSA Investigations Transparency Act. H.R. 6084, ERISA Litigation Reform Act. S. 4498, ABLE Tomorrow Act.
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Medicare/Medicaid
H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues Part D redesign and policy issues including non-interference and rebates policy issues Part B policy issues Drug cost and pricing policy issues Medicare rebate policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues CMS IPAY Guidance on the Medicare Drug Price Negotiation Program IPAY and Maximum Fair Prices policy issues Medicaid rebate policy issues GENErating cost Reductions for U.S. Medicaid (GENEROUS) model Global Benchmark for Efficient Drug Pricing (GLOBE) Proposed Rule Guarding U.S. Medicare Against Rising Drugs Costs (GUARD) Proposed Rule
Client expense: $890,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2026 · first_quarter · Energy/Nuclear
-Issues related to energy efficiency tax credits in the Inflation Reduction Act of 2022 (H.R.5376) -Issues related to the One Big Beautiful Bill Act (H.R.1) -Issues related to the ENERGY STAR program
Client expense: $50,000 · Firm income: Not reported
Government targets: Energy, Dept of, Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Environment/Superfund
Issues related to the implementation of H.R. 3684, the Infrastructure Investment and Jobs Act (IIJA). Issues related to Buy America. Issues related to energy and environmental permitting reform. Issues related to permitting reform in H.R. 1, the Lower Energy Costs Act. Issues related to the implementation of H.R. 5376, the Inflation Reduction Act of 2022.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Transportation, Dept of (DOT)
2026 · first_quarter · Medicare/Medicaid
H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) S. 1637: MVP Act Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues Part D redesign and policy issues including non-interference and rebates policy issues Part B policy issues Drug cost and pricing policy issues Medicare rebate policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues CMS IPAY Guidance on the Medicare Drug Price Negotiation Program IPAY and Maximum Fair Prices policy issues Medicaid rebate policy issues GENErating cost Reductions for U.S. Medicaid (GENEROUS) model Global Benchmark for Efficient Drug Pricing (GLOBE) Proposed Rule Guarding U.S. Medicare Against Rising Drugs Costs (GUARD) Proposed Rule
Client expense: $1,640,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2026 · first_quarter · Taxation/Internal Revenue Code
Implementation of H.R.5376, Inflation Reduction Act of 2022 Implementation of H.R. 1- The One Big Beautiful Bill Act
Client expense: $250,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Taxation/Internal Revenue Code
The One Big Beautiful Bill Act (H.R.1): issues related to the tax treatment of retirement savings. Implementation of SECURE 2.0 Act of 2022. Retirement Savings for Americans Act. Allowing 403(b) plans to invest in collective investment trusts. Capital gains and dividends taxation. Excise tax on corporate stock buybacks.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Taxation/Internal Revenue Code
Monitor and engage on federal legislation and administrative action related to modifications to international corporate taxes, including scheduled effective rate increases in the Global Intangible Low-Taxed Income (GILTI) tax, Base Erosion and Anti-Abuse Tax (BEAT), and Foreign-Derived Intangible Income (FDII) tax. Monitor and engage on federal legislation and administrative action related to modifications to international corporate taxes proposed by the Organisation for Economic Co-operation and Development (OECD) BEPS 2.0 process Pillar 2 global minimum tax rules. Monitor and engage on federal legislation and administrative action related to modifications to the corporate tax rate. Monitor and engage on federal legislation and administrative action related to extension of full expensing for research and development. Monitor and engage on federal legislation and administrative action related to Superfund tax, including but not limited to S. 615, Chemical Tax Repeal Act, and H.R. 640, Chemical Tax Repeal Act. Monitor and engage on federal legislation and administrative action related to taxation and deductibility of corporate interest payments. Monitor and engage on federal legislation and administrative action related to implementation of P.L. 117-169, Inflation Reduction Act of 2022. Monitor and engage on tax credits for recycling infrastructure. Monitor and engage on federal legislation and administrative action related to bonus depreciation tax incentives. Monitor and engage on the implementation of H.R.1, One Big Beautiful Bill Act (P.L. 119-21). H.R. 4466, CIRCLE Act. S. 1605, International Competition for American Jobs Act.
Client expense: $1,760,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
2026 · first_quarter · Health Issues
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act H.R.5526 Biosimilar Red Tape Elimination Act HR 7391 Community Health Center Drug Pricing Protection Act
Client expense: $2,580,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · first_quarter · Medicare/Medicaid
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S.3345, PBM Price Transparency and Accountability Act HR 6166, Lowering Drug Costs for American Families Act S 3019 - No Big Blockbuster Bailouts Act S 3349 PBM Disclosure Act HR 4317 PBM Reform Act Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act (EPIC) HR 1672 Maintaining Investments in New Innovation Act (MINI) HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 PL 119-75 Consolidated Appropriations Act of 2026
Client expense: $2,580,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · first_quarter · Taxation/Internal Revenue Code
HR 1 / PL 119-21 One Big Beautiful Bill Act. HR 2547/S 1335 Secure Family Futures Act. Issue: debt investment tax change from capital to ordinary. Public Law 117-169. Issue: implementation of corporate minimum tax. S ___ Protecting Proper Life Insurance (PPLI) from Abuse Act. Issue: private placement life insurance. No bill number. Issue: life insurance tax stabilization.
Client expense: $460,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Medicare/Medicaid
Treat and Reduce Obesity Act; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169) implementation. Pharmacy benefit manager reform proposals. H.R. 1, One Big Beautiful Bill Act, issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Medicare/Medicaid
General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. IPI drug pricing proposal, Medicare Rebate Rule. Drug pricing legislation, Medicare rebate reform, and proposals to impose "most favored nation" pricing on Medicare Part B and D. "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 1492 and S. 832. H.R. 1, "One Big Beautiful Bill Act", issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Medicare/Medicaid
H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) S. 1637: MVP Act Inflation Reduction Act of 2022 (Public Law No. 117-169) implementation policy issues Part D redesign and policy issues including non-interference and rebates policy issues Part B policy issues Drug cost and pricing policy issues Medicare rebate policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues CMS IPAY Guidance on the Medicare Drug Price Negotiation Program IPAY and Maximum Fair Prices policy issues Medicaid rebate policy issues GENErating cost Reductions for U.S. Medicaid (GENEROUS) model Global Benchmark for Efficient Drug Pricing (GLOBE) Proposed Rule Guarding U.S. Medicare Against Rising Drugs Costs (GUARD) Proposed Rule
Client expense: $12,210,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · first_quarter · Taxation/Internal Revenue Code
H.R. 1, One Big Beautiful Bill Act" (PL 119-21) implementation, regulations. " Inflation Reduction Act of 2022" (PL 117-169), regulations and implementation."
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Taxation/Internal Revenue Code
Monitor implementation of utility-related tax provisions of the Inflation Reduction Act of 2022 and other related provisions contained in HR 1, FY-25 reconciliation bill.
Client expense: Not reported · Firm income: $110,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Taxation/Internal Revenue Code
Issues related to tax incentives for retirement savings. Issues related to electronic delivery of IRC- and ERISA-mandated statements and disclosures. Issues related to recordkeeping simplification for 401(k) plans. Issues related to lifetime income and auto features. Issues related to alternative investments in retirement plans. Technical Corrections to the SECURE 2.0 Act of 2022. S. 1831, Auto Reenroll Act. H.R. 1. H.R. 2958, Balance the Scales Act. H.R. 2869, EBSA Investigations Transparency Act. H.R. 6084, ERISA Litigation Reform Act.
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Taxation/Internal Revenue Code
Electric vehicle charging infrastructure and electric vehicle tax credits in P.L. 117-169 (Inflation Reduction Act of 2022). H.R.1 - One Big Beautiful Bill Act
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Energy/Nuclear
-Issues related to energy efficiency tax credits in the Inflation Reduction Act of 2022 (H.R.5376) -Issues related to the One Big Beautiful Bill Act (H.R.1) -Issues related to the ENERGY STAR program
Client expense: $50,000 · Firm income: Not reported
Government targets: Energy, Dept of, Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Environment/Superfund
Issues related to the implementation of H.R. 3684, the Infrastructure Investment and Jobs Act (IIJA). Issues related to Buy America. Issues related to energy and environmental permitting reform. Issues related to permitting reform in H.R. 1, the Lower Energy Costs Act. Issues related to the implementation of H.R. 5376, the Inflation Reduction Act of 2022.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Transportation, Dept of (DOT)
2025 · fourth_quarter · Transportation
H.R 5376 Inflation Reduction Act of 2022, Electric Vehicle consumer tax credits, Electric Vehicle Charging tax credits and incentives, vehicle manufacturing incentives and programs, Charging and Fueling Infrastructure (CFI) Grant Program, Federal Excise Tax for zero-emission trucks, Clean School Bus Program, fleet electrification. H.R. 1 One Big Beautiful Bill Act
Client expense: Not reported · Firm income: $20,000
Government targets: Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Transportation, Dept of (DOT), Treasury, Dept of
2025 · fourth_quarter · Energy/Nuclear
H.R 5376 Inflation Reduction Act of 2022, Electric Vehicle consumer tax credits, Electric Vehicle Charging tax credits and incentives, vehicle manufacturing incentives and programs, Charging and Fueling Infrastructure (CFI) Grant Program, Federal Excise Tax for zero-emission trucks, Clean School Bus Program, fleet electrification. H.R. 1 One Big Beautiful Bill Act
Client expense: Not reported · Firm income: $20,000
Government targets: Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Transportation, Dept of (DOT), Treasury, Dept of
2025 · fourth_quarter · Environment/Superfund
H.R 5376 Inflation Reduction Act of 2022, Electric Vehicle consumer tax credits, Electric Vehicle Charging tax credits and incentives, vehicle manufacturing incentives and programs, Charging and Fueling Infrastructure (CFI) Grant Program, Federal Excise Tax for zero-emission trucks, Clean School Bus Program, fleet electrification. H.R. 1 One Big Beautiful Bill Act
Client expense: Not reported · Firm income: $20,000
Government targets: Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Transportation, Dept of (DOT), Treasury, Dept of
2025 · fourth_quarter · Taxation/Internal Revenue Code
Inflation Reduction Act of 2022 (Public Law 117-169) - provisions related to clean energy tax incentives. H.R. 1 (now P.L. 119-21) - provisions related to clean energy tax incentives.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
2025 · fourth_quarter · Taxation/Internal Revenue Code
HR 1 / PL 119-21 One Big Beautiful Bill Act. HR 2547/S 1335 Secure Family Futures Act. Issue: debt investment tax change from capital to ordinary. Public Law 117-169. Issue: implementation of corporate minimum tax. S ___ Protecting Proper Life Insurance (PPLI) from Abuse Act. Issue: private placement life insurance. No bill number. Issue: life insurance tax stabilization.
Client expense: $300,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Taxation/Internal Revenue Code
The One Big Beautiful Bill Act (H.R.1): issues related to the tax treatment of retirement savings. Implementation of SECURE 2.0 Act of 2022. Retirement Savings for Americans Act. Allowing 403(b) plans to invest in collective investment trusts. Capital gains and dividends taxation. Excise tax on corporate stock buybacks.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Medicare/Medicaid
H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) S. 1637: MVP Act Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues Part D redesign and policy issues including non-interference and rebates policy issues Part B policy issues Drug cost and pricing policy issues Medicare rebate policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues CMS IPAY Guidance on the Medicare Drug Price Negotiation Program IPAY and Maximum Fair Prices policy issues Medicaid rebate policy issues GENErating cost Reductions for U.S. Medicaid (GENEROUS) model Global Benchmark for Efficient Drug Pricing (GLOBE) Proposed Rule Guarding U.S. Medicare Against Rising Drugs Costs (GUARD) Proposed Rule
Client expense: $810,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2025 · fourth_quarter · Medicare/Medicaid
Treat and Reduce Obesity Act; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169) implementation. Pharmacy benefit manager reform proposals. H.R. 1, One Big Beautiful Bill Act, issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Taxation/Internal Revenue Code
Monitor and engage on federal legislation and administrative action related to modifications to international corporate taxes, including scheduled effective rate increases in the Global Intangible Low-Taxed Income (GILTI) tax, Base Erosion and Anti-Abuse Tax (BEAT), and Foreign-Derived Intangible Income (FDII) tax. Monitor and engage on federal legislation and administrative action related to modifications to international corporate taxes proposed by the Organisation for Economic Co-operation and Development (OECD) BEPS 2.0 process Pillar 2 global minimum tax rules. Monitor and engage on federal legislation and administrative action related to modifications to the corporate tax rate. Monitor and engage on federal legislation and administrative action related to extension of full expensing for research and development. Monitor and engage on federal legislation and administrative action related to Superfund tax, including but not limited to S. 615, Chemical Tax Repeal Act, and H.R. 640, Chemical Tax Repeal Act. Monitor and engage on federal legislation and administrative action related to taxation and deductibility of corporate interest payments. Monitor and engage on federal legislation and administrative action related to implementation of P.L. 117-169, Inflation Reduction Act of 2022. Monitor and engage on tax credits for recycling infrastructure. Monitor and engage on federal legislation and administrative action related to bonus depreciation tax incentives. Monitor and engage on the implementation of H.R.1, One Big Beautiful Bill Act (P.L. 119-21). H.R. 4466, CIRCLE Act.
Client expense: $910,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
2025 · fourth_quarter · Medicare/Medicaid
General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. IPI drug pricing proposal, Medicare Rebate Rule. Drug pricing legislation, Medicare rebate reform, and proposals to impose "most favored nation" pricing on Medicare Part B and D. "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 1492 and S. 832. H.R. 1, "One Big Beautiful Bill Act", issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Medicare/Medicaid
Issues related to drug pricing Issues related to Public law 117-1769 Inflation Reduction Act Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment HR 946 Optimizing Research Progress Hope and New Cures Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025 S.3345, PBM Price Transparency and Accountability Act H.R. 6166, Lowering Drug Costs for American Families Act S.3019 - No Big Blockbuster Bailouts Act H.Res. 928 - Affirming support for most-favored-Nation drug pricing for United States patients S 3349 PBM Disclosure Act HR 4317 PBM Reform Act
Client expense: $3,550,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE